A Phase 3 interventional study of ARD-0403 in Hypogonadism, sponsored by Ardana Bioscience Ltd. Completed at 12 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-04-18.
Sponsored by Ardana Bioscience Ltd · Phase 3, Interventional, and Treatment
Male hypogonadism, a disorder associated with testosterone deficiency, is frequently seen in clinical practice and has significant effects on patient wellbeing. The purpose of this study is to investigate the efficacy and safety of ARD-0403 as a testosterone replacement therapy in testosterone deficient men.
345 studies on the registry are indexed under Hypogonadism; 43 are open to participants now.
This study's planned enrollment of 150 is above the median of 56 across 260 interventional studies indexed under Hypogonadism.
Browse Hypogonadism studies →Ardana Bioscience Ltd is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
ARD-0403
Pharmacokinetic
Safety and tolerability
This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ardana Bioscience Ltd